Apolipoprotein E controls the risk and age at onset of Parkinson diseaseYi‐Ju Li, Jeffery M. Vance, Jean Hubble et al.|Neurology|2004Cited by 145
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's diseaseJ. Thomas Hutton, Jerry L. Morris, William C. Koller et al.|Neurology|1996Cited by 89
Factors Predictive of the Need for Levodopa Therapy in Early, Untreated Parkinson's DiseaseMichael McDermott, Joseph Jankovic, J. Carter et al.|Archives of Neurology|1995Cited by 60
The α-synuclein gene is not a major risk factor in familial Parkinson diseaseWilliam K. Scott, Larry H. Yamaoka, Jeffrey M. Stajich et al.|Neurogenetics|1999Cited by 29
Interest in predictive testing for Parkinson's disease: Impact of neuroprotective therapyNabila Dahodwala, Andrew Siderowf, James L. Connolly et al.|Parkinsonism & Related Disorders|2007Cited by 20